tiprankstipranks
Hester Biosciences Limited (IN:HESTERBIO)
:HESTERBIO
India Market
Want to see IN:HESTERBIO full AI Analyst Report?

Hester Biosciences Limited (HESTERBIO) Price & Analysis

0 Followers

HESTERBIO Stock Chart & Stats

₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)

Bulls Say, Bears Say

Bulls Say
Revenue GrowthMulti-year revenue expansion with a 2026 re-acceleration (~10.8%) points to enduring demand for Hester's veterinary vaccines and animal-health offerings. Steady top-line growth supports scale benefits, predictable production planning, and the ability to fund R&D and geographic expansion over the medium term.
Profitability RecoveryA return to solid net margins (~16.7%) and better operating profit indicates the company has improved cost structure and pricing execution. Durable margin recovery enhances cash conversion potential, strengthens internal funding for growth initiatives, and reduces sensitivity to cyclical revenue swings.
Improving Cash GenerationConsistent positive free cash flow in 2024–2026, with FCF covering ~70% of net income in 2026, shows earnings are increasingly translating into usable cash. This durable cash generation supports debt reduction, reinvestment in production capacity, and more resilient funding for commercial expansion.
Bears Say
Margin And Earnings VolatilityMaterial swings in gross and net margins reduce earnings predictability and complicate multi-period planning. Persistent volatility can hinder consistent reinvestment, make budgeting for capacity or R&D riskier, and leave the company exposed to input cost, disease-cycle, or pricing pressures over the medium term.
Weak Debt Coverage By Operating CashOperating cash flow failing to reliably cover debt obligations exposes the business to refinancing and liquidity risk if profits falter. Low coverage limits flexibility for opportunistic investments, increases sensitivity to higher interest costs, and makes capital structure management more challenging over time.
Elevated Absolute Debt HistoricallyAlthough debt-to-equity has improved, the company carried elevated absolute leverage in prior years. Persistent indebtedness can constrain strategic optionality, increase fixed costs, and reduce resilience to margin or revenue shocks, limiting long-term capital allocation flexibility.

Hester Biosciences Limited News

HESTERBIO FAQ

What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2347.70 in the past 12 months.
    What is Hester Biosciences Limited’s market cap?
    Hester Biosciences Limited’s market cap is ₹17.74B.
      When is Hester Biosciences Limited’s upcoming earnings report date?
      Hester Biosciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
        How were Hester Biosciences Limited’s earnings last quarter?
        Hester Biosciences Limited released its earnings results on May 15, 2026. The company reported ₹18.787 earnings per share for the quarter, beating the consensus estimate of N/A by ₹18.787.
          Is Hester Biosciences Limited overvalued?
          According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Hester Biosciences Limited pay dividends?
            Hester Biosciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 0.44%. See more information on Hester Biosciences Limited dividends here
              What is Hester Biosciences Limited’s EPS estimate?
              Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Hester Biosciences Limited have?
              Hester Biosciences Limited has 8,506,865 shares outstanding.
                What happened to Hester Biosciences Limited’s price movement after its last earnings report?
                Hester Biosciences Limited reported an EPS of ₹18.787 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.669%.
                  Which hedge fund is a major shareholder of Hester Biosciences Limited?
                  Currently, no hedge funds are holding shares in IN:HESTERBIO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Hester Biosciences Limited

                    Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.

                    Hester Biosciences Limited (HESTERBIO) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Gufic Biosciences Limited
                    Indoco Remedies Limited
                    Morepen Laboratories Limited
                    Unichem Laboratories Limited
                    Popular Stocks